{"schema_version":"secwatch.filing_event.v1","accession":"0001453687-26-000087","form_type":"8-K","ticker":"RNAC","cik":"0001453687","company_name":"Cartesian Therapeutics, Inc.","filed_at":"2026-05-26T11:08:51+00:00","discovered_at":"2026-05-26T11:10:00.237897+00:00","generated_at":"2026-05-26T11:12:52.292203+00:00","sec_items":["1.01","2.03","3.02","5.02","7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.85,"confidence":"high","headline":"Cartesian secures up to $150M debt facility; CMO resigns; Phase 3 data expected Q1 2027","bullets":["Secured up to $150M credit facility with K2 HealthVentures; initial $50M tranche funded at close on May 22, 2026.","Term loans bear interest at 8.95% or prime+2.20% (whichever greater); matures June 1, 2030 with monthly amortization from July 2029.","CMO Milos Miljkovic resigns effective May 31, 2026; will receive severance including six months' salary and COBRA coverage.","Phase 3 AURORA topline data for Descartes-08 in myasthenia gravis expected in Q1 2027; BLA filing planned for mid-2027.","Cash runway extended into 2028; Phase 2 TRITON and Phase 1/2 HELIOS data expected in H1 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001453687-26-000087","json":"https://secwatch.observer/filing/0001453687-26-000087.json","markdown":"https://secwatch.observer/filing/0001453687-26-000087.md","text":"https://secwatch.observer/filing/0001453687-26-000087.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453687/000145368726000087/0001453687-26-000087-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453687/000145368726000087/rnac-20260522.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T11:12:52.292203+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0b672e6ba1","claim":"Milos Miljkovic resigned as Chief Medical Officer at Cartesian Therapeutics, Inc..","evidence_excerpt":"On May 22, 2026, Milos Miljkovic, M.D., the Company’s Chief Medical Officer, delivered a notice of resignation to the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368726000087/0001453687-26-000087-index.htm","confidence":0.95}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}